Moderate–high efficacy disease-modifying therapies reduce relapse risk in late-onset multiple sclerosis

Disease-modifying treatment and disability progression in subclasses of patients with primary progressive MS: results from the Big MS Data Network

Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis

Utility of icobrain for brain volumetry in multiple sclerosis clinical practice

Prevalence of Progression Independent of Relapse Activity and Relapse-Associated Worsening in Patients With AQP4-IgG-Positive NMOSD

Disease Activity in Pregnant and Postpartum Women With Multiple Sclerosis Receiving Ocrelizumab or Other Disease-Modifying Therapies